- Home
- BSX
as 04-18-2025 12:32pm EST
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Upcoming Earnings Alert:
Get ready for potential market movements as Boston Scientific Corporation BSX prepares to release earnings report on 23 Apr 2025.
| Founded: | 1979 | Country: | United States |
| Employees: | 53000 | City: | MARLBOROUGH |
| Market Cap: | 138.5B | IPO Year: | 1992 |
| Target Price: | $107.61 | AVG Volume (30 days): | 10.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 23 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.25 | EPS Growth: | 16.82 |
| 52 Week Low/High: | $66.80 - $107.17 | Next Earning Date: | 04-23-2025 |
| Revenue: | $16,747,000,000 | Revenue Growth: | 17.61% |
| Revenue Growth (this year): | 15.6% | Revenue Growth (next year): | 10.28% |
Stock Insider Trading Activity of Boston Scientific Corporation (BSX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mahoney Michael F | BSX | Chairman, President & CEO | Apr 1 '25 | Sell | $100.01 | 164,442 | $16,445,071.54 | 1,594,530 | |
| Brown Vance R | BSX | SVP, GC and Corp. Secretary | Mar 21 '25 | Sell | $100.85 | 4,826 | $486,702.10 | 41,019 | |
| Woodworth Emily | BSX | SVP, Global Controller and CAO | Mar 3 '25 | Sell | $104.80 | 7,631 | $800,896.51 | 914 | |
| Woodworth Emily | BSX | SVP, Global Controller and CAO | Feb 28 '25 | Sell | $101.13 | 9,887 | $999,872.31 | 914 | |
| Mirviss Jeffrey B. | BSX | EVP&Pres, Periph Intervent | Feb 24 '25 | Sell | $104.13 | 7,363 | $766,920.75 | 25,766 | |
| Zane Ellen M | BSX | Director | Feb 24 '25 | Sell | $104.23 | 13,586 | $1,416,133.99 | 34,944 | |
| Brown Vance R | BSX | SVP, GC and Corp. Secretary | Feb 21 '25 | Sell | $104.64 | 4,826 | $504,992.64 | 41,019 | |
| Mirviss Jeffrey B. | BSX | EVP&Pres, Periph Intervent | Feb 19 '25 | Sell | $105.35 | 1,510 | $159,078.50 | 25,766 | |
| Brennan Daniel J. | BSX | EVP and CFO | Feb 18 '25 | Sell | $104.66 | 84,863 | $8,919,295.52 | 232,618 | |
| Sorenson John Bradley | BSX | EVP, Global Operations | Feb 18 '25 | Sell | $104.80 | 5,960 | $624,860.60 | 20,991 |
Latest Boston Scientific Corporation News
BSX Breaking Stock News: Dive into BSX Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors
Investor's Business Daily
2 days ago
These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth
Zacks
2 days ago
Should You Buy Boston Scientific Stock Ahead of Q1 Earnings?
TipRanks
2 days ago
Reddit initiated, Target downgraded: Wall Street’s top analyst calls
Insider Monkey
2 days ago
Boston Scientific Corporation (BSX): Among the Innovative Healthcare Stocks to Watch in 2025
Zacks
2 days ago
Boston Scientific (BSX) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
Zacks
2 days ago
Should You Continue to Hold Veracyte Stock in Your Portfolio?
Simply Wall St.
2 days ago
Boston Scientific (NYSE:BSX) Ticks All The Boxes When It Comes To Earnings Growth
Compare BSX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BSX Boston Scientific Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.